SG Americas Securities LLC increased its position in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 45.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,060 shares of the biopharmaceutical company’s stock after acquiring an additional 3,794 shares during the period. SG Americas Securities LLC’s holdings in Intra-Cellular Therapies were worth $190,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ITCI. BB Biotech AG boosted its position in Intra-Cellular Therapies by 11.7% in the second quarter. BB Biotech AG now owns 2,150,000 shares of the biopharmaceutical company’s stock valued at $26,703,000 after buying an additional 225,000 shares in the last quarter. Wasatch Advisors Inc. boosted its position in Intra-Cellular Therapies by 65.1% in the second quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock valued at $20,611,000 after buying an additional 654,400 shares in the last quarter. State Street Corp boosted its position in Intra-Cellular Therapies by 10.4% in the second quarter. State Street Corp now owns 1,004,360 shares of the biopharmaceutical company’s stock valued at $12,474,000 after buying an additional 94,763 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Intra-Cellular Therapies by 419.3% in the second quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock valued at $8,038,000 after buying an additional 522,565 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Intra-Cellular Therapies by 336.1% in the second quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock valued at $7,213,000 after buying an additional 447,586 shares in the last quarter. Institutional investors and hedge funds own 74.47% of the company’s stock.

A number of analysts have weighed in on the stock. Piper Jaffray Companies upgraded shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their target price for the company from $14.00 to $33.00 in a research report on Thursday, September 7th. Cowen restated an “outperform” rating and issued a $27.00 target price (up previously from $20.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. SunTrust Banks upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. BTIG Research restated a “buy” rating and issued a $36.00 target price on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. Finally, Canaccord Genuity assumed coverage on shares of Intra-Cellular Therapies in a research report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $25.67.

In other Intra-Cellular Therapies news, major shareholder Alafi Capital Co Llc purchased 258,065 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was purchased at an average price of $15.50 per share, with a total value of $4,000,007.50. Following the completion of the purchase, the insider now owns 3,953,270 shares of the company’s stock, valued at $61,275,685. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard A. Lerner sold 7,000 shares of the firm’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $15.09, for a total transaction of $105,630.00. Following the transaction, the director now directly owns 8,621 shares of the company’s stock, valued at approximately $130,090.89. The disclosure for this sale can be found here. Insiders have sold 26,400 shares of company stock valued at $410,693 in the last ninety days. Insiders own 19.80% of the company’s stock.

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) opened at $15.69 on Friday. The stock has a market cap of $856.32, a price-to-earnings ratio of -7.16 and a beta of 0.72. Intra-Cellular Therapies Inc. has a 52 week low of $7.85 and a 52 week high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.53). The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.06 million. Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The company’s revenue for the quarter was up 675.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.70) earnings per share. equities analysts predict that Intra-Cellular Therapies Inc. will post -2.13 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “SG Americas Securities LLC Has $190,000 Position in Intra-Cellular Therapies Inc. (ITCI)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://theolympiareport.com/2017/12/24/sg-americas-securities-llc-has-190000-position-in-intra-cellular-therapies-inc-itci.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.